EP3814381A4 - Trispecific antagonists - Google Patents

Trispecific antagonists Download PDF

Info

Publication number
EP3814381A4
EP3814381A4 EP19826335.2A EP19826335A EP3814381A4 EP 3814381 A4 EP3814381 A4 EP 3814381A4 EP 19826335 A EP19826335 A EP 19826335A EP 3814381 A4 EP3814381 A4 EP 3814381A4
Authority
EP
European Patent Office
Prior art keywords
trispecific
antagonists
trispecific antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19826335.2A
Other languages
German (de)
French (fr)
Other versions
EP3814381A1 (en
Inventor
Jackie Z. SHENG
Bo Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gensun Biopharma Inc
Original Assignee
Gensun Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gensun Biopharma Inc filed Critical Gensun Biopharma Inc
Publication of EP3814381A1 publication Critical patent/EP3814381A1/en
Publication of EP3814381A4 publication Critical patent/EP3814381A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP19826335.2A 2018-06-29 2019-06-28 Trispecific antagonists Pending EP3814381A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862691658P 2018-06-29 2018-06-29
US201962823989P 2019-03-26 2019-03-26
PCT/US2019/039982 WO2020006511A1 (en) 2018-06-29 2019-06-28 Trispecific antagonists

Publications (2)

Publication Number Publication Date
EP3814381A1 EP3814381A1 (en) 2021-05-05
EP3814381A4 true EP3814381A4 (en) 2022-08-10

Family

ID=68985227

Family Applications (3)

Application Number Title Priority Date Filing Date
EP19826335.2A Pending EP3814381A4 (en) 2018-06-29 2019-06-28 Trispecific antagonists
EP19824955.9A Pending EP3813880A4 (en) 2018-06-29 2019-06-28 Antitumor immune checkpoint regulator antagonists
EP19826236.2A Withdrawn EP3813864A4 (en) 2018-06-29 2019-06-28 Antitumor antagonists

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP19824955.9A Pending EP3813880A4 (en) 2018-06-29 2019-06-28 Antitumor immune checkpoint regulator antagonists
EP19826236.2A Withdrawn EP3813864A4 (en) 2018-06-29 2019-06-28 Antitumor antagonists

Country Status (9)

Country Link
US (8) US10647773B2 (en)
EP (3) EP3814381A4 (en)
JP (3) JP2021529557A (en)
KR (1) KR20210028222A (en)
CN (3) CN112638401A (en)
AU (1) AU2019293047A1 (en)
BR (1) BR112020026862A2 (en)
CA (1) CA3105101A1 (en)
WO (3) WO2020006516A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
IL290457B1 (en) 2015-12-30 2024-10-01 Kodiak Sciences Inc Antibodies and conjugates thereof
CN109071656B (en) * 2017-01-05 2021-05-18 璟尚生物制药公司 Checkpoint modulator antagonists
MX2020009152A (en) 2018-03-02 2020-11-09 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof.
CN112638401A (en) * 2018-06-29 2021-04-09 璟尚生物制药公司 Antitumor antagonists
TWI760751B (en) * 2019-05-29 2022-04-11 美商美國禮來大藥廠 Tigit and pd-1/tigit-binding molecules
CN114340735A (en) * 2019-06-28 2022-04-12 璟尚生物制药公司 Antitumor antagonist composed of mutated TGF beta 1-RII extracellular domain and immunoglobulin scaffold
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN114616251B (en) * 2019-10-21 2024-05-24 南京维立志博生物科技有限公司 Recombinant proteins targeting PD-1 and TGF beta
IL292613A (en) 2019-11-01 2022-07-01 Ares Trading Sa Combined inhibition of pd-1, tgfβ and atm together with radiotherapy for the treatment of cancer
KR20220097443A (en) 2019-11-05 2022-07-07 메르크 파텐트 게엠베하 Combination inhibition of PD-1, TGFβ and TIGIT for the treatment of cancer
BR112022013403A2 (en) * 2020-01-10 2022-10-11 Shanghai Henlius Biotech Inc ANTI-TIGIT ANTIBODIES, MULTISPECIFIC ANTIBODIES THAT COMPRISE THEM AND METHODS OF USE THEREOF
CA3137211A1 (en) * 2020-03-20 2021-09-23 Remegen Co., Ltd. Bispecific fusion protein and application thereof
WO2021209458A1 (en) 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
CN115461362A (en) 2020-04-14 2022-12-09 葛兰素史密斯克莱知识产权发展有限公司 Cancer combination therapy based on ICOS antibody and PD-L1 antibody TGF-beta receptor fusion protein
MX2022013620A (en) * 2020-04-29 2023-01-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd Bifunctional protein against pd-1 and tgf-î².
TW202216778A (en) 2020-07-15 2022-05-01 美商安進公司 Tigit and cd112r blockade
JP2023538891A (en) 2020-08-19 2023-09-12 ゼンコア インコーポレイテッド Anti-CD28 composition
WO2022059800A1 (en) * 2020-09-15 2022-03-24 Santen Pharmaceutical Co., Ltd. Bispecific binding molecules against vegf and ang2
CN116801906A (en) 2020-11-02 2023-09-22 阿雷斯贸易股份有限公司 Combination therapy for cancer
WO2022090529A1 (en) 2020-11-02 2022-05-05 Ares Trading S.A. Combination treatment of cancer
CN114539415B (en) * 2020-11-24 2024-02-02 普米斯生物技术(珠海)有限公司 anti-PD-L1/VEGF/TGF-beta multi-specific antibody and application thereof
WO2022132932A1 (en) * 2020-12-15 2022-06-23 The Trustees Of Columbia University In The City Of New York Method of enhancing immune response and cancer immunotherapy by targeting the cd58:cd2 axis
CN116917334A (en) * 2021-02-22 2023-10-20 浙江道尔生物科技有限公司 Multi-domain fusion protein with anticancer activity
CN115322259A (en) * 2021-05-11 2022-11-11 正大天晴药业集团南京顺欣制药有限公司 Bifunctional proteins against PD-1 and TGF-beta
US20240279324A1 (en) * 2021-06-03 2024-08-22 Gensun Biopharma Inc. Multispecific antagonists
AU2022288571A1 (en) 2021-06-07 2024-01-04 Ares Trading S.A. Combination treatment of cancer
IL308918A (en) * 2021-06-09 2024-01-01 Shanghai Epimab Biotherapeutics Co Ltd Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1
CA3226397A1 (en) 2021-07-22 2023-01-26 Ignacio Moraga GONZALEZ Therapeutic muteins
WO2023040935A1 (en) * 2021-09-15 2023-03-23 江苏恒瑞医药股份有限公司 Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
CN113773401B (en) * 2021-09-15 2023-06-20 宜明昂科生物医药技术（上海）股份有限公司 Recombinant fusion protein targeting CD47 and PD-L1 and preparation and application thereof
CN118159568A (en) * 2021-10-21 2024-06-07 杭州阿诺生物医药科技有限公司 Fusion polypeptide and application thereof
WO2023116911A1 (en) * 2021-12-24 2023-06-29 百奥泰生物制药股份有限公司 ANTI-FRα ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF
WO2023137395A1 (en) * 2022-01-13 2023-07-20 Ingenia Therapeutics Inc. Vegf and tie2-binding fusion protein and uses thereof
CN116496407A (en) * 2022-01-25 2023-07-28 赋生康(上海)生物科技有限公司 Double-function fusion protein and preparation method and application thereof
CN116836281A (en) * 2022-03-25 2023-10-03 英诺湖医药(杭州)有限公司 B7H3 antibody and bifunctional antibody comprising same
WO2024017281A1 (en) * 2022-07-20 2024-01-25 明慧医药（杭州）有限公司 Multispecific antibody and use thereof
WO2024041477A1 (en) * 2022-08-22 2024-02-29 浙江道尔生物科技有限公司 Use of multi-domain fusion protein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170275353A1 (en) * 2016-03-24 2017-09-28 Gensun Biopharma Inc Trispecific inhibitors for cancer treatment

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3030025A (en) 1962-04-17 Thermostatic gas valve
GB2116183B (en) 1982-03-03 1985-06-05 Genentech Inc Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US7067637B1 (en) 1992-02-12 2006-06-27 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Antibody or antibody fragments specific for a protein of the TGF-β family
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
EP1947183B1 (en) * 1996-08-16 2013-07-17 Merck Sharp & Dohme Corp. Mammalian cell surface antigens; related reagents
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
DK0973804T3 (en) 1997-04-07 2007-05-07 Genentech Inc Anti-VEGF antibodies
EP1025228A4 (en) 1997-10-21 2002-09-18 Human Genome Sciences Inc Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
JP2002502607A (en) 1998-02-09 2002-01-29 ジェネンテク・インコーポレイテッド Novel tumor necrosis factor receptor homologs and nucleic acids encoding the same
US6376653B1 (en) 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
EP1196186B1 (en) 1999-07-12 2007-10-31 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
JP2001206899A (en) 1999-11-18 2001-07-31 Japan Tobacco Inc HUMAN MONOCLONAL ANTIBODY AGAINST TGF-beta II TYPE RECEPTOR AND MEDICINAL USE THEREOF
US6528959B2 (en) 2000-07-19 2003-03-04 Honda Giken Kogyo Kabushiki Kaisha Driving force control system for front-and-rear wheel drive vehicles
MXPA03002918A (en) * 2000-10-02 2004-04-20 Arizeke Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR THE TRANSPORT OF BIOLOGICALLY ACTIVE AGENTS THROUGH CELLULAR BARRIERS.
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
JP2005526506A (en) 2002-03-04 2005-09-08 イムクローン システムズ インコーポレイティド KDR specific human antibody and use thereof
US7575893B2 (en) 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
BRPI0410785A (en) 2003-05-23 2006-06-20 Wyeth Corp isolated nucleic acid molecule, host cell, non-human transgenic animal, isolated protein, antisense oligonucleotide, sirna molecule, isolated antibody, screening methods for test compounds capable of inhibiting, enhancing or mimicking gitrl interaction with gitr, to diagnose disease, to treat a patient at risk or diagnosed with a disease, to induce and to inhibit the proliferation of a cell population containing effector cells, to block the suppression and suppression of a cell population that includes t cells. effectors in the presence of cd4 + cd25 + regulatory t cells, and to treat a disease, pharmaceutical composition, and vaccine adjuvant
MXPA05012723A (en) 2003-05-30 2006-02-08 Genentech Inc Treatment with anti-vegf antibodies.
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7182135B2 (en) 2003-11-14 2007-02-27 Halliburton Energy Services, Inc. Plug systems and methods for using plugs in subterranean formations
JP2007518399A (en) 2003-12-02 2007-07-12 ジェンザイム コーポレイション Compositions and methods for diagnosing and treating lung cancer
JP5128935B2 (en) 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド Humanized anti-TGF-β antibody
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
WO2006083289A2 (en) 2004-06-04 2006-08-10 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
US8143380B2 (en) * 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
EP2845865A1 (en) 2004-11-12 2015-03-11 Xencor Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
DK1866339T3 (en) 2005-03-25 2013-09-02 Gitr Inc GTR-binding molecules and their applications
UA93201C2 (en) 2005-04-22 2011-01-25 Эли Лилли Энд Компани Antibody neutralizing human tgf beta 1
US20090041783A1 (en) 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
WO2006138627A2 (en) 2005-06-16 2006-12-28 Inhibitex, Inc. Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
ES2379194T3 (en) 2005-12-23 2012-04-23 Eli Lilly And Company TGF-beta binding antibodies
WO2007133822A1 (en) 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
CN101801413A (en) 2007-07-12 2010-08-11 托勒克斯股份有限公司 Combination therapies employing GITR binding molecules
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
CN102203258A (en) 2008-07-02 2011-09-28 新兴产品开发西雅图有限公司 TGF-b antagonist multi-target binding proteins
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
WO2010030002A1 (en) 2008-09-12 2010-03-18 国立大学法人三重大学 Cell capable of expressing exogenous gitr ligand
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
PL2417156T3 (en) 2009-04-07 2015-07-31 Roche Glycart Ag Trivalent, bispecific antibodies
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
ME02505B (en) 2009-12-29 2017-02-20 Aptevo Res & Development Llc Heterodimer binding proteins and uses thereof
DK2542590T4 (en) * 2010-03-05 2020-07-13 Univ Johns Hopkins COMPOSITIONS AND PROCEDURE FOR TARGETED IMMUNOMODULATORY ANTIBODIES AND FUSION PROTEINS
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
KR20140054303A (en) 2011-08-19 2014-05-08 리제너론 파아마슈티컬스, 인크. Anti-tie2 antibodies and uses thereof
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
HUE044263T2 (en) 2012-03-30 2019-10-28 Boehringer Ingelheim Int Ang2-binding molecules
CA2876397C (en) 2012-06-15 2019-08-06 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
WO2014062659A2 (en) 2012-10-15 2014-04-24 Oncomed Pharmaceuticals, Inc. Methods of treating ocular diseases
JP6571527B2 (en) 2012-11-21 2019-09-04 ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドＷｕｈａｎ Ｙｚｙ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． Bispecific antibody
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
US20160137717A1 (en) * 2013-06-20 2016-05-19 Gabriela Burian Use of a vegf antagonist in treating choroidal neovascularisation
US9873740B2 (en) * 2013-07-16 2018-01-23 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
MX2016010067A (en) * 2014-02-10 2016-10-07 Merck Patent Gmbh TARGETED TGFß INHIBITION.
EP3593812A3 (en) * 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
KR102349370B1 (en) * 2014-05-26 2022-01-10 삼성전자주식회사 Humanized or Affinity-matured Anti ANG-2 antibody and uses thereof
CN113583131B (en) 2014-08-19 2024-09-03 默沙东有限责任公司 Anti-TIGIT antibodies
RU2017119428A (en) * 2014-11-06 2018-12-06 Дженентек, Инк. COMBINED THERAPY, INCLUDING THE USE OF OX40-CONNECTING AGONISTS AND TIGIT INHIBITORS
SG11201705063VA (en) * 2014-12-23 2017-07-28 Bristol Myers Squibb Co Antibodies to tigit
CN107431522B (en) 2015-04-10 2021-03-16 Lg 电子株式会社 Method for reporting channel state information in wireless communication system and apparatus therefor
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
TWI715587B (en) * 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Tigit-binding agents and uses thereof
CN105111314B (en) * 2015-08-13 2019-01-08 成都百世博生物技术有限公司 A kind of new fusion protein, pharmaceutical composition and its preparation method and application
US20200231652A1 (en) * 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
CA3007135A1 (en) * 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Novel anti-pd-l1 antibodies
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
EP3471753A1 (en) * 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 and il-2 cytokines
CN109071656B (en) * 2017-01-05 2021-05-18 璟尚生物制药公司 Checkpoint modulator antagonists
CN112638401A (en) * 2018-06-29 2021-04-09 璟尚生物制药公司 Antitumor antagonists
CN114340735A (en) * 2019-06-28 2022-04-12 璟尚生物制药公司 Antitumor antagonist composed of mutated TGF beta 1-RII extracellular domain and immunoglobulin scaffold
CN116390940A (en) * 2020-09-23 2023-07-04 海正生物制药有限公司 TGFBR2-ECD mutant, fusion protein containing same and application
US20240279324A1 (en) * 2021-06-03 2024-08-22 Gensun Biopharma Inc. Multispecific antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170275353A1 (en) * 2016-03-24 2017-09-28 Gensun Biopharma Inc Trispecific inhibitors for cancer treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOUSSEN ANTONIA M ET AL: "Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data", EYE, NATURE PUBLISHING GROUP, GB, vol. 35, no. 5, 9 February 2021 (2021-02-09), pages 1305 - 1316, XP037436614, ISSN: 0950-222X, [retrieved on 20210209], DOI: 10.1038/S41433-020-01377-X *
SAHARINEN PIPSA ET AL: "Therapeutic targeting of the angiopoietin-TIE pathway", NATURE REVIEWS DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB, vol. 16, no. 9, 19 May 2017 (2017-05-19), pages 635 - 661, XP037134871, ISSN: 1474-1776, [retrieved on 20170519], DOI: 10.1038/NRD.2016.278 *

Also Published As

Publication number Publication date
CN112638401A (en) 2021-04-09
US20200002439A1 (en) 2020-01-02
JP2021532170A (en) 2021-11-25
AU2019293047A1 (en) 2021-01-28
US11851493B2 (en) 2023-12-26
US11667716B2 (en) 2023-06-06
US20210246214A1 (en) 2021-08-12
WO2020006516A1 (en) 2020-01-02
US20210009696A1 (en) 2021-01-14
CN113056285A (en) 2021-06-29
US20200002426A1 (en) 2020-01-02
BR112020026862A2 (en) 2021-04-20
US20200181272A1 (en) 2020-06-11
US11945873B2 (en) 2024-04-02
WO2020006509A1 (en) 2020-01-02
WO2020006511A1 (en) 2020-01-02
CN112739717A (en) 2021-04-30
JP2021529557A (en) 2021-11-04
US20200002417A1 (en) 2020-01-02
US11518813B2 (en) 2022-12-06
EP3813880A4 (en) 2022-07-13
EP3814381A1 (en) 2021-05-05
US10647773B2 (en) 2020-05-12
KR20210028222A (en) 2021-03-11
JP2021529556A (en) 2021-11-04
US20200277388A1 (en) 2020-09-03
US10597453B2 (en) 2020-03-24
CA3105101A1 (en) 2020-01-02
EP3813864A4 (en) 2022-07-20
US11001635B2 (en) 2021-05-11
EP3813864A1 (en) 2021-05-05
EP3813880A1 (en) 2021-05-05
US20230331857A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
EP3814381A4 (en) Trispecific antagonists
EP3803740A4 (en) Blockchain overwatch
EP3801265A4 (en) Uroflowmeter
EP3755311A4 (en) Indane-amines as pd-l1 antagonists
EP3772961A4 (en) Fungicidal combinations
EP3486371B8 (en) Rail-switching unit
GB201905552D0 (en) Antagonists
EP3758510A4 (en) An ingredient
EP3784463A4 (en) Fluorosulfones
EP3721129A4 (en) Cryosphere
EP3856177A4 (en) Grapiprant unit dosage forms
EP3825124A4 (en) Multilayer structure
EP3876716A4 (en) Cryo-carrier
EP3834079A4 (en) Multi-question multi-answer configuration
EP3773733A4 (en) Metallo-liothyronine
GB201815629D0 (en) Antagonists
EP3831190A4 (en) Combine
EP3818976A4 (en) Structure
EP3738602A4 (en) Cytocide
EP3993793A4 (en) P2x7r antagonists
IL283413A (en) Antagonists
AU2018101027A4 (en) PadPay
EP3830662A4 (en) Plant-monitor
EP3797079A4 (en) Cryoliner
EP3554260A4 (en) Feed ingredient

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101ALI20220404BHEP

Ipc: A61K 45/06 20060101ALI20220404BHEP

Ipc: A61K 39/395 20060101ALI20220404BHEP

Ipc: C07K 16/18 20060101AFI20220404BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20220713

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101ALI20220707BHEP

Ipc: A61K 45/06 20060101ALI20220707BHEP

Ipc: A61K 39/395 20060101ALI20220707BHEP

Ipc: C07K 16/18 20060101AFI20220707BHEP